Scientists have opened a new view into the workings of the central nervous system, finding a diverse set of important molecules.

The Department of Energy’s Vehicle Technologies Office recently issued two awards to researchers at PNNL for their contributions to areas that are crucial for the expansion of electric vehicles.

PNNL has named Biomedical Scientist Tom Metz, an expert on metabolomics and multi-omics within the Biological Sciences Division, a 2023 Laboratory Fellow.

Small teams in the Biological Sciences Division at PNNL and at EMSL—the Environmental and Molecular Sciences Laboratory, an Office of Science user facility at PNNL—are pros at preparation.

Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.

Joshua Adkins and Jamie Lo will lead PMedIC, Pacific Northwest National Laboratory and Oregon Health & Science University’s joint research institute.

PNNL scientists are creating new ways to learn more about the vast sea of chemicals that haven't been identified—yet.

Metabolomics analysis revealed differences in metabolome profiles for two distinct modes of fungal wood decay.

Methods review suggests ways to use artificial intelligence and machine learning to handle missing data when integrating two or more omics approaches.

PNNL’s Isabella van Rooyen leads the JOM special section on Additive Manufacturing for High Temperature Energy Systems.

The PNNL-patented ShAPE™ manufacturing process produces high-strength aluminum vehicle parts that lower costs and are more environmentally friendly.

PNNL chemist Christopher Anderton recently named president-elect of the Imaging Mass Spectrometry Society (IMSS). In this new position, he will help lead the merge of IMSS with a European-based society, currently underway.

PNNL senior materials scientist Keerti Kappagantula has been named to the 2023 Nominating Committee of ASM International.

A PNNL-developed computational framework accurately predicts the thermomechanical history and microstructure evolution of materials designed using solid phase processing, allowing scientists to custom design metals with desired properties.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.

Exploring why some brains are more resilient to the impact of Alzheimer’s disease could lead to improved diagnoses, treatment and prevention.

Advanced proteomic analysis tools dig deep into human blood plasma to understand the molecular nature of advanced alcoholic disease.

A detailed snapshot of proteins by PNNL scientists marks a big step toward a diagnostic blood test for a deadly form of liver disease.

The work by the team at PNNL takes a critical step in leveraging ML to accelerate advanced manufacturing R&D, specifically for manufacturing techniques without access to efficient, first-principles simulations.

PNNL will partner with Commonwealth Fusion Systems to develop innovative steel materials for fusion applications under the INFUSE program